Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

110.99 +2.39 (+2.20%)

Official Closing Price Updated: 7:00 PM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection

November 19, 2025

From Merck & Co., Inc.

Via Business Wire

European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union

November 19, 2025

From Merck & Co., Inc.

Via Business Wire

Cidara Therapeutics Stock Rockets Over 700% This Year — Then Wall Street Turns Neutral On Merck Takeover ↗

November 17, 2025

Via Stocktwits

Healthcare Sector Navigates Volatile Markets: A Defensive Anchor or Driven by Innovation?

November 18, 2025

As broader markets grapple with persistent volatility on November 18, 2025, the healthcare sector within the S&P 500 (SPX) finds itself under intense scrutiny. Traditionally viewed as a stalwart...

Via MarketMinute

Which S&P500 stocks are moving on Tuesday? ↗

November 18, 2025

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday.

Via Chartmill

Market Movers in Motion: Merck & Co. and Amer Sports Chart Volatile Courses

November 18, 2025

The financial markets are a constant theater of dynamic shifts, and in recent months, two distinct players – pharmaceutical giant Merck & Co. and global sporting goods powerhouse Amer Sports – have...

Via MarketMinute

Topics Economy Initial Public Offering Intellectual Property

Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything ↗

November 18, 2025

Via MarketBeat

Tech Stocks Drop, Pharma Gains As Sector Rotation Picks Up: What's Moving Markets Tuesday? ↗

November 18, 2025

Wall Street endured another wave of selling in tech stocks on Tuesday, with the Nasdaq 100 down more than 1% by midday in New York, extending its month-to-date slide to more than 5%.

Via Benzinga

Which S&P500 stocks have an unusual volume on Tuesday? ↗

November 18, 2025

Let's have a look at what is happening on the US markets on Tuesday. Below you can find the S&P500 stocks with an unusual volume in today's session.

Via Chartmill

Merck's Winrevair Success Extends Beyond Pulmonary Hypertension, Showing Promise In Complex Heart Condition ↗

November 18, 2025

Merck's Winrevair drug achieved its primary goal in the Phase 2 CADENCE study for combined post- and pre-capillary pulmonary hypertension due to HFpEF.

Via Benzinga

Uncover the latest developments among S&P500 stocks in today's session. ↗

November 18, 2025

Curious about the top performers within the S&P500 index in the middle of the day on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Via Chartmill

Merck Announces First-Quarter 2026 Dividend

November 18, 2025

From Merck & Co., Inc.

Via Business Wire

Merck Jumps On A Surprise Win; Why It Still Has A Long Road To Go ↗

November 18, 2025

Merck stock jumped Tuesday on a surprise win for its drug, sotatercept, in patients with pulmonary hypertension.

Via Investor's Business Daily

Topics Government

Top S&P500 movers in Tuesday's pre-market session ↗

November 18, 2025

Discover the top S&P500 movers in Tuesday's pre-market session and stay informed about market dynamics.

Via Chartmill

Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗

November 18, 2025

Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model.

Via Investor's Business Daily

Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)

November 18, 2025

From Merck & Co., Inc.

Via Business Wire

Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring ↗

November 17, 2025

AI breakthroughs in pharma are pushing Eli Lilly and healthcare stocks higher—and may soon reshape how we fight cancer.

Via Benzinga

Topics Artificial Intelligence

Hedge Funds Snap Up Eli Lilly, United Healthcare, And More, Putting Healthcare ETFs Back In The Spotlight ↗

November 17, 2025

With funds buying Eli Lilly, UNH, and other pharma giants, healthcare ETFs can emerge as key beneficiaries of a broader defensive rotation.

Via Benzinga

Topics ETFs

Market Grapples with Valuation Fears Amidst Accelerating Sector Rotation

November 17, 2025

As November 2025 unfolds, the global financial markets find themselves at a critical juncture, characterized by a palpable sense of unease over elevated valuations in specific sectors and a pronounced...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Top 2 Health Care Stocks That May Fall Off A Cliff This Month ↗

November 17, 2025

Via Benzinga

MERCK & CO. INC. (NYSE:MRK): A Value Investment with Strong Fundamentals ↗

November 17, 2025

Discover Merck (MRK), a top value stock with a low P/E ratio, strong profitability, and solid financial health, offering a potential margin of safety.

Via Chartmill

These 2 Dividend ETFs Are a Retiree's Best Friend ↗

November 16, 2025

Exchange-traded funds provide investors with exposure to a basket of stocks. Some also pay dividends.

Via The Motley Fool

Topics Artificial Intelligence Bonds ETFs

AI Revolutionizes Drug Shelf-Life: Optimized Stability Models Promise Safer, More Effective Medicines

November 14, 2025

The pharmaceutical industry is on the cusp of a profound transformation, driven by the integration of data science and Artificial Intelligence (AI) into drug formulation stability models. This...

Via TokenRing AI

Topics Artificial Intelligence Economy Product Recall

AI and Digital Twins Ignite a New Era of Accelerated Drug Discovery and Development

November 14, 2025

The pharmaceutical industry is on the cusp of a profound transformation, driven by the synergistic power of artificial intelligence (AI) and digital twins. These cutting-edge technologies are rapidly...

Via TokenRing AI

Topics Artificial Intelligence

Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025

November 14, 2025

The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Merck Swoops In On Buyout Bonanza With A $9.2 Billion Cidara Therapeutics Deal ↗

November 14, 2025

The company is getting deeper into the antiviral space, buying a company working on a long-acting drug to protect against flu.

Via Investor's Business Daily

Merck Makes Big Bet On Flu Protection With Cidara Buyout ↗

November 14, 2025

Merck (NYSE: MRK) to acquire Cidara (NASDAQ: CDTX) for $9.2 billion, diversifying its portfolio with CD388.

Via Benzinga

Merck To Buy Cidara In $9.2B Deal To Strengthen Antiviral Portfolio ↗

November 14, 2025

With the new deal, Merck would gain access to CD388, currently in late-stage development, and designed to prevent influenza infection in individuals at higher risk of influenza complications.

Via Stocktwits

Topics Intellectual Property

Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

November 14, 2025

From Merck & Co., Inc.

Via Business Wire

Cidara Therapeutics Stock Soars 42% After-Hours On Merck Buyout Buzz — Retail Traders Eye A Potential Blowout Premium ↗

November 13, 2025

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.